Search Results - "ten Bokkel Huinink, Wim W"

Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study by TEN BOKKEL HUININK, Wim W, SUFLIARSKY, Jozef, SMIT, Willem M, SPANIK, Stanislav, WAGNEROVA, Maria, HIRTE, Hal W, KAYE, Stan, JOHRI, Anandhi R, OZA, Amit M

“…PURPOSE To evaluate the safety, maximum tolerated dose (MTD), and pharmacokinetics of patupilone administered once every 3 weeks with proactive standardized…”
Get full text

Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer by VAN DEN BELT-DUSEBOUT, Alexandra W, NUVER, Janine, DE WIT, Ronald, GIETEMA, Jourik A, TEN BOKKEL HUININK, Wim W, RODRIGUS, Patrick T. R, SCHIMMEL, Erik C, ALEMAN, Berthe M. P, VAN LEEUWEN, Flora E

“…To evaluate the long-term risk of cardiovascular disease (CVD) in survivors of testicular cancer (TC). We compared CVD incidence in 2,512 5-year survivors of…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors by BOSS, David S, SIEGEL- LAKHAI, Wandena S, VAN EGMOND-SCHOEMAKER, Nadja E, PLUIM, Dick, ROSING, Hilde, TEN BOKKEL HUININK, Wim W, BEIJNEN, Jos H, SCHELLENS, Jan H. M

“…Purpose: Preclinical studies have shown that the combination of topotecan and carboplatin is synergistic. To evaluate the schedule dependency of this…”
Get full text

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours by SCHOEMAKER, Nadja E, KUPPENS, I. E. L. M, TEN BOKKEL HUININK, Wim W, LEFEBVRE, Patricia, BEIJNEN, Jos H, ASSADOURIAN, Sylvie, SANDERINK, Ger-Jan, SCHELLENS, Jan H. M

“…A phase I study was conducted with oral irinotecan given daily for 14 days every 3 weeks in 45 patients with solid tumours to establish the maximum tolerated…”
Get full text

Coadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel by MALINGRE, Mirte M, RICHEL, Dick J, BEIJNEN, Jos H, ROSING, Hilde, KOOPMAN, Franciska J, TEN BOKKEL HUININK, Wim W, SCHOT, Margaret E, SCHELLENS, Jan H. M

“…Oral bioavailability of docetaxel is very low, which is, at least in part, due to its affinity for the intestinal drug efflux pump P-glycoprotein (P-gp). In…”
Get full text

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel by Meerum Terwogt, Jetske M, ten Bokkel Huinink, Wim W, Schellens, Jan HM, Schot, Margaret, Mandjes, Ingrid AM, Zurlo, Maria G, Rocchetti, Marurizio, Rosing, Hilde, Koopman, Franciska J, Beijnen, Jos H

“…Intravenous administration of paclitaxel is hindered by poor water solubility of the drug. Currently, paclitaxel is dissolved in a mixture of ethanol and…”
Get full text

Co-administration of cyclosporin enables oral therapy with paclitaxel by Terwogt, Jetske M Meerum, Beijnen, Jos H, Huinink, Wim W ten Bokkel, Rosing, Hilde, Schellens, Jan HM

“…Terwogt et al determined whether co-administration of cyclosporin (Cs) might increase the absorption of oral paclitaxel. Co-administration of the P-gp…”
Get full text

Phase I and Pharmacokinetic Study of Oral Paclitaxel by MALINGRE, M. M, TERWOGT, J. M. M, SCHELLENS, J. H. M, BEIJNEN, J. H, ROSING, H, KOOPMAN, F. J, VAN TELLINGEN, O, DUCHIN, K, TEN BOKKEL HUININK, W. W, SWART, M, LIEVERST, J

“…To investigate dose escalation of oral paclitaxel in combination with dose increment and scheduling of cyclosporine (CsA) to improve the systemic exposure to…”
Get full text

Urinary and fecal excretion of topotecan in patients with malignant solid tumours by HERBEN, Virginie M. M, SCHOEMAKER, Nadja E, ROSING, Hilde, VAN ZOMEREN, Desiree M, TEN BOKKEL HUININK, Wim W, DUBBELMAN, Ria, HEARN, Solange, SCHELLENS, Jan H. M, BEIJNEN, Jos H

“…The objectives of the study were to determine the pharmacokinetics and routes of excretion of topotecan following intravenous or oral administration to…”
Get full text

Coadministration of Oral Cyclosporin A Enables Oral Therapy with Paclitaxel by TERWOGT, J. M. M, MALINGRE, M. M, BEIJNEN, J. H, TEN BOKKEL HUININK, W. W, ROSING, H, KOOPMAN, F. J, VAN TELLINGEN, O, SWART, M, SCHELLENS, J. H. M

“…i.v. paclitaxel is inconvenient and associated with significant and poorly predictable side effects largely due to the pharmaceutical vehicle Cremophor EL…”
Get full text

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients by Meerum Terwogt, Jetske M, van Tellingen, Olaf, Nannan Panday, Vinodh R, Huizing, Manon T, Schellens, Jan HM, ten Bokkel Huinink, Wim W, Boschma, Marcel US, Giaccone, Giuseppe, Veenhof, Cees HN, Beijnen, Jos H

“…The purpose of our study was to investigate the pharmacokinetics of Cremophor EL following administration of escalating doses of Taxol (paclitaxel dissolved in…”
Get full text

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin by TERWOGT, Jetske M, GROENEWEGEN, Gerard, BEIJNEN, Jos H, SCHELLENS, Jan H. M, PLUIM, Dick, MALIEPAARD, Marc, TIBBEN, Matthijs M, HUISMAN, Albert, TEN BOKKEL HUININK, Wim W, SCHOT, Margaret, WELBANK, Helen, VOEST, Emile E

“…To investigate the safety and pharmacokinetics of a new liposomal formulation of cisplatin, SPI-77, in patients with advanced malignancies. Patients with…”
Get full text

Phase I and Pharmacokinetic Study of Irinotecan Administered as a Low-Dose, Continuous Intravenous Infusion Over 14 Days in Patients With Malignant Solid Tumors by HERBEN, V. M. M, SCHELLENS, J. H. M, SWART, M, GRUIA, G, VERNILLET, L, BEIJNEN, J. H, TEN BOKKEL HUININK, W. W

“…To evaluate the feasibility of administering irinotecan as a continuous intravenous infusion for 14 to 21 days. Patients with solid tumors refractory to…”
Get full text

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A by MALINGRE, Mirte M, BEIJNEN, Jos H, ROSING, Hilde, KOOPMAN, Franciska J, VAN TELLINGEN, Olaf, DUCHIN, Ken, TEN BOKKEL HUININK, Wim W, SWART, Martha, LIEVERST, Jan, SCHELLENS, Jan H. M

“…To investigate dose escalation of bi-daily (b.i.d.) oral paclitaxel in combination with cyclosporin A in order to improve and prolong the systemic exposure to…”
Get full text

Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian Cancer by HERBEN, V. M. M, NANNAN PANDAY, V. R, TEN BOKKEL HUININK, W. W, RICHEL, D. J, SCHELLENS, J. H. M, VAN DER VANGE, N, ROSING, H, BEUSENBERG, F. D, HEARN, S, DOYLE, E, BEIJNEN, J. H

“…To evaluate the feasibility of administering topotecan in combination with paclitaxel and cisplatin without and with granulocyte colony-stimulating factor…”
Get full text

The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel by Malingré, Mirte M, Beijnen, Jos H, Rosing, Hilde, Koopman, Franciska J, van Tellingen, Olaf, Duchin, Ken, ten Bokkel Huinink, Wim W, Swart, Martha, Lieverst, Jan, Schellens, Jan HM

“…The objective of this study was to define the minimally effective dose of cyclosporin A (CsA) that would result in a maximal increase of the systemic exposure…”
Get full text

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration by Malingré, Mirte M, Schellens, Jan HM, van Tellingen, Olaf, Rosing, Hilde, Koopman, Franciska J, Duchin, Ken, ten Bokkel Huinink, Wim W, Swart, Martha, Beijnen, Jos H

“…The objective of this study was to compare the quantitative excretion of paclitaxel and metabolites after i.v. and oral drug administration. Four patients…”
Get full text

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel by Malingré, Mirte M, Ten Bokkel Huinink, Wim W, Duchin, Ken, Schellens, Jan HM, Beijnen, Jos H

“…The objective of this study was to evaluate the pharmacokinetics of oral cyclosporin A (CsA) when co-administered to enhance the oral absorption of paclitaxel…”
Get full text

Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer by Herben, V M, ten Bokkel Huinink, W W, Schot, M E, Hudson, I, Beijnen, J H

“…Preclinical schedule dependency suggests that prolonged maintenance of low plasma levels of topotecan, a specific inhibitor of the nuclear enzyme topoisomerase…”
Get more information

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel–cisplatin–topotecan in a phase I study by Schoemaker, Nadja E, Herben, Virginie MM, de Jong, Laurina A, van Waardenburg, Robert CAM, Pluim, Dick, ten Bokkel Huinink, Wim W, Beijnen, Jos H, Schellens, Jan HM

“…Topotecan stabilizes the topoisomerase I (Topo I) cleavable complex. We measured Topo I levels in white blood cells of patients with ovarian cancer treated…”
Get full text